Garmin Q3 profit beats estimates on margin expansion; raises outlook

By Reuters News


Overview

  • Switzerland-based GPS device maker's Q3 revenue rose 12% yr/yr, meeting analyst expectations

  • Q3 operating income and net income both beat analyst estimates

  • Company raised full-year 2026 guidance after record Q3 results


Outlook

  • Garmin raises 2026 revenue guidance to $8.15 bln

  • Company now expects 2026 pro forma EPS of $10.80

  • Garmin sees 2026 gross margin at 61.0% and operating margin at 29.0%


Result Drivers

  • PRODUCT AND MARKET STRENGTH - Co said broad-based demand and new product launches contributed to record results, per CEO Cliff Pemble

  • MARGIN EXPANSION - Higher gross margin attributed to favorable segment mix, lower product cost, and tariff refunds

  • SEGMENT GROWTH - Fitness, outdoor, and marine segments saw double-digit revenue growth, led by wearables, adventure watches, and sonar products


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Meet

$1.99 bln

$1.99 bln (4 Analysts)

Q3 Pro forma EPS

$2.76

Q3 EPS

$2.80

Q3 Net Income

Beat

$541.66 mln

$468.43 mln (4 Analysts)

Q3 Gross Margin

63.30%

Q3 Operating income

Beat

$611.65 mln

$535.03 mln (4 Analysts)

Q3 Pretax Profit

$661.12 mln


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 6 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the communications & networking peer group is "buy."

  • Wall Street's median 12-month price target for Garmin Ltd. is $293.00, about 1.3% above its October 27 closing price of $289.34

  • The stock recently traded at 26 times the next 12-month earnings vs. a P/E of 24 three months ago


Reuters Recommended Reads

  • Oct 27 - Switzerland's INFICON Q3 sales jump, lifts FY outlook on firm semiconductor demand

  • Oct 27 - Logitech beats profit forecast as sales of gaming, conferencing products rise

  • Oct 27 - Novartis slightly misses Q3 net sales estimates, but tops core EPS view


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.